Literature DB >> 12799254

Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma.

John O Mason1, David H Fischer.   

Abstract

PURPOSE: To report the use of intrathecal chemotherapy for two patients with recurrent central nervous system (CNS) intraocular lymphoma.
DESIGN: Two interventional case reports. PARTICIPANTS: The clinical course of two patients with documented recurrent CNS intraocular lymphoma were retrospectively reviewed. INTERVENTION: Both patients had previously undergone external beam radiation therapy to the orbit and brain, as well as systemic methotrexate (MTX) and intrathecal cytarabine (Ara-C), for primary CNS intraocular lymphoma. Both patients developed recurrent CNS intraocular lymphoma and treatment involved intrathecal MTX and Ara-C delivered by means of an Ommaya reservoir. MAIN OUTCOME MEASURE: Survival and resolution of intraocular lymphoma.
RESULTS: Complete remission of the CNS intraocular lymphoma was seen in both patients. Both patients maintain reading visual acuity in at least one eye. Both patients remain disease free with lymphoma in remission for greater than 5 years after initial diagnosis.
CONCLUSIONS: Intrathecal chemotherapy for recurrent CNS intraocular lymphoma seems to be effective in preserving vision and possibly increasing survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799254     DOI: 10.1016/S0161-6420(03)00268-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

Review 1.  Management of primary intraocular lymphoma.

Authors:  Stella K Kim; Chi-Chao Chan; Dana J Wallace
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 2.  Primary intraocular lymphoma: a review.

Authors:  Gregory S Vosganian; Saskia Boisot; Kathrin I Hartmann; William R Freeman; Robert W Sharpe; Prabhakar Tripuraneni; Alan Saven
Journal:  J Neurooncol       Date:  2011-05-31       Impact factor: 4.130

Review 3.  Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features.

Authors:  Sarah E Coupland; Heinrich Heimann; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-29       Impact factor: 3.117

4.  Chemotherapy in newly diagnosed primary central nervous system lymphoma.

Authors:  Nooshin Hashemi-Sadraei; David M Peereboom
Journal:  Ther Adv Med Oncol       Date:  2010-07       Impact factor: 8.168

Review 5.  Intraocular lymphoma.

Authors:  Li-Juan Tang; Chang-Lin Gu; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

Review 6.  Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature.

Authors:  Kristoph Jahnke; Nikolaos E Bechrakis; Sarah E Coupland; Alexander Schmittel; Michael H Foerster; Lars Fischer; Eckhard Thiel; Agnieszka Korfel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

Review 7.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

8.  Diagnosis and management of primary intraocular lymphoma: an update.

Authors:  Kristoph Jahnke; Eckhard Thiel; Lauren E Abrey; Edward A Neuwelt; Agnieszka Korfel
Journal:  Clin Ophthalmol       Date:  2007-09

9.  Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changes.

Authors:  Ebru B Ozkan; Altan A Ozcan; Hande Taylan Sekeroglu; Yurdun Kuyucu; Hulya Ozgun; Sait Polat
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

Review 10.  Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma.

Authors:  Min Zhou; Gezhi Xu
Journal:  Taiwan J Ophthalmol       Date:  2016-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.